The tumour suppressor hSNF5/INI1 controls the differentiation potential of malignant rhabdoid cells

European Journal of Cancer

Volumn 42, Issue 14, 2006, Pages 2326-2334

  Albanese, Patricia ^a   Belin, Marie France ^b   Delattre, Olivier ^a  

^a INSTITUT CURIE   (France)

^b INSERM   (France)

Author keywords

Differentiation; Neural; PC12 cells; Rhabdoid; Suppressor

Indexed keywords

ARTICLE; CANCER CELL; CELL DIFFERENTIATION; CHROMATIN ASSEMBLY AND DISASSEMBLY; CLINICAL FEATURE; CONTROLLED STUDY; FLUORESCENCE ACTIVATED CELL SORTING; GENE MUTATION; GLIA CELL; HUMAN; HUMAN CELL; NERVE CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHABDOID TUMOR; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

EID: 33748100218     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2006.03.028     Document Type: Article

References (35)

1. Haas J.E., Palmer N.F., Weinberg A.G., and Beckwith J.B. Ultrastructure of malignant rhabdoid tumor of the kidney. A distinctive renal tumor of children. Hum Pathol 12 7 (1981) 646-657
2. Schmidt D., Harms D., and Zieger G. Malignant rhabdoid tumor of the kidney. Histopathology, ultrastructure and comments on differential diagnosis. Virchows Arch A Pathol Anat Histopathol 398 1 (1982) 101-108
3. Karnes P.S., Tran T.N., Cui M.Y., Bogenmann E., Shimada H., and Ying K.L. Establishment of a rhabdoid tumor cell line with a specific chromosomal abnormality, 46,XY,t(11;22)(p15.5;q11.23). Cancer Genet Cytogenet 56 1 (1991) 31-38
4. Staehelin F., Bissig H., Hosli I., et al. Inv(11)(p13p15) and myf-3(MyoD1) in a malignant extrarenal rhabdoid tumor of a premature newborn. Pediatr Res 48 4 (2000) 463-467
5. Parham D.M., Peiper S.C., Robicheaux G., Ribeiro R.C., and Douglass E.C. Malignant rhabdoid tumor of the liver. Evidence for epithelial differentiation. Arch Pathol Lab Med 112 1 (1988) 61-64
6. Fanburg-Smith J.C., Hengge M., Hengge U.R., Smith Jr. J.S., and Miettinen M. Extrarenal rhabdoid tumors of soft tissue: a clinicopathologic and immunohistochemical study of 18 cases. Ann Diagn Pathol 2 6 (1998) 351-362
7. Versteege I., Sevenet N., Lange J., et al. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature 394 6689 (1998) 203-206
8. Sevenet N., Sheridan E., Amram D., Schneider P., Handgretinger R., and Delattre O. Constitutional mutations of the hSNF5/INI1 gene predispose to a variety of cancers. Am J Hum Genet 65 5 (1999) 1342-1348
9. Sevenet N., Lellouch-Tubiana A., Schofield D., et al. Spectrum of hSNF5/INI1 somatic mutations in human cancer and genotype-phenotype correlations. Hum Mol Genet 8 13 (1999) 2359-2368
10. Biegel J.A., Zhou J.Y., Rorke L.B., Stenstrom C., Wainwright L.M., and Fogelgren B. Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer Res 59 1 (1999) 74-79
11. Guidi C.J., Sands A.T., Zambrowicz B.P., et al. Disruption of Ini1 leads to peri-implantation lethality and tumorigenesis in mice. Mol Cell Biol 21 10 (2001) 3598-3603
12. Roberts C.W., Galusha S.A., McMenamin M.E., Fletcher C.D., and Orkin S.H. Haploinsufficiency of Snf5 (integrase interactor 1) predisposes to malignant rhabdoid tumors in mice. Proc Natl Acad Sci USA 97 25 (2000) 13796-13800
13. Klochendler-Yeivin A., Fiette L., Barra J., Muchardt C., Babinet C., and Yaniv M. The murine SNF5/INI1 chromatin remodeling factor is essential for embryonic development and tumor suppression. EMBO Rep 1 6 (2000) 500-506
14. Roberts C.W., Leroux M.M., Fleming M.D., and Orkin S.H. Highly penetrant, rapid tumorigenesis through conditional inversion of the tumor suppressor gene Snf5. Cancer Cell 2 5 (2002) 415-425
15. Pedersen T.A., Kowenz-Leutz E., Leutz A., and Nerlov C. Cooperation between C/EBPalpha TBP/TFIIB and SWI/SNF recruiting domains is required for adipocyte differentiation. Genes Dev 15 23 (2001) 3208-3216
16. de la Serna I.L., Carlson K.A., and Imbalzano A.N. Mammalian SWI/SNF complexes promote MyoD-mediated muscle differentiation. Nat Genet 27 2 (2001) 187-190
17. Strobeck M.W., Knudsen K.E., Fribourg A.F., et al. BRG-1 is required for RB-mediated cell cycle arrest. Proc Natl Acad Sci USA 97 14 (2000) 7748-7753
18. Zhang H.S., Gavin M., Dahiya A., et al. Exit from G1 and S phase of the cell cycle is regulated by repressor complexes containing HDAC-Rb-hSWI/SNF and Rb-hSWI/SNF. Cell 101 1 (2000) 79-89
19. Versteege I., Medjkane S., Rouillard D., and Delattre O. A key role of the hSNF5/INI1 tumor suppressor in the control of the G1-S transition of the cell cycle. Oncogene 21 42 (2002) 6403-6412
20. Betz B.L., Strobeck M.W., Reisman D.N., Knudsen E.S., and Weissman B.E. Re-expression of hSNF5/INI1/BAF47 in pediatric tumor cells leads to G1 arrest associated with induction of p16ink4a and activation of RB. Oncogene 21 34 (2002) 5193-5203
21. Zhang Z.K., Davies K.P., Allen J., et al. Cell cycle arrest and repression of cyclin D1 transcription by INI1/hSNF5. Mol Cell Biol 22 16 (2002) 5975-5988
22. Ae K., Kobayashi N., Sakuma R., et al. Chromatin remodeling factor encoded by ini1 induces G1 arrest and apoptosis in ini1-deficient cells. Oncogene 21 20 (2002) 3112-3120
23. Reincke B.S., Rosson G.B., Oswald B.W., and Wright C.F. INI1 expression induces cell cycle arrest and markers of senescence in malignant rhabdoid tumor cells. J Cell Physiol 194 3 (2003) 303-313
24. Giraudon P., Dufay N., Hardin H., Reboul A., Tardy M., and Belin M.F. Differentiation of a medulloblastoma cell line towards an astrocytic lineage using the human T lymphotropic retrovirus-1. Neuroscience 52 4 (1993) 1069-1079
25. Medjkane S., Novikov E., Versteege I., and Delattre O. The tumor suppressor hSNF5/INI1 modulates cell growth and actin cytoskeleton organization. Cancer Res 64 10 (2004) 3406-3413
26. Hendrix M.J., Seftor E.A., Hess A.R., and Seftor R.E. Vasculogenic mimicry and cell-cell plasticity: lessons from melanoma. Nat Rev Cancer 3 6 (2003) 411-421 Review
27. Xie S., Luca M., Huang S., et al. Expression of MCAM/MUC18 by human melanoma cells leads to increased tumor growth and metastasis. Cancer Res 57 11 (1997) 2295-2303
28. Yan X., Lin Y., Yang D., et al. A novel anti-CD146 monoclonal antibody, AA98, inhibits angiogenesis and tumor growth. Blood 102 1 (2003) 184-191
29. Derrington E.A., Dufay N., Rudkin B.B., and Belin M.F. Human primitive neuroectodermal tumor cells behave as multipotent neural precursors in response to FGF2. Oncogene 17 13 (1998) 1663-1672
30. Buzanska L., Spassky N., Belin M.F., et al. Human medulloblastoma cell line DEV is a potent tool to screen for factors influencing differentiation of neural stem cells. J Neurosci Res 65 1 (2001) 17-23
31. Bultman S., Gebuhr T., Yee D., et al. A Brg1 null mutation in the mouse reveals functional differences among mammalian SWI/SNF complexes. Mol Cell 6 6 (2000) 1287-1295
32. Gregg R.G., Willer G.B., Fadool J.M., Dowling J.E., and Link B.A. Positional cloning of the young mutation identifies an essential role for the Brahma chromatin remodeling complex in mediating retinal cell differentiation. Proc Natl Acad Sci USA 100 11 (2003) 6535-6540
33. Link B.A., Fadool J.M., Malicki J., and Dowling J.E. The zebrafish young mutation acts non-cell-autonomously to uncouple differentiation from specification for all retinal cells. Development 127 10 (2000) 2177-2188
34. Seo S., Richardson G.A., and Kroll K.L. The SWI/SNF chromatin remodeling protein Brg1 is required for vertebrate neurogenesis and mediates transactivation of Ngn and NeuroD. Development 132 1 (2005) 105-115
35. Nusser N., Gosmanova E., Zheng Y., and Tigyi G. Nerve growth factor signals through TrkA, phosphatidylinositol 3-kinase, and Rac1 to inactivate RhoA during the initiation of neuronal differentiation of PC12 cells. J Biol Chem 277 39 (2002) 35840-35846